Key result
Clinical pharmacist-led interventions may slow heart failure progression through targeted education and risk management.
Why the study?
The prevalence of cardiac disease increases with age, and clinical pharmacist involvement in risk identification, education, awareness programs, and lifestyle modification may help reduce the progression of heart failure severity.
Does clinical pharmacist management reduce the progression of disease severity in patients with congestive heart failure?
Does clinical pharmacist management reduce the progression of disease severity in patients with congestive heart failure?
This brief review highlights how clinical pharmacists can help mitigate the progression of congestive heart failure through risk identification, education, awareness programs, and lifestyle modifications.
Answers are grounded in this paper and cite their sources.
Supports pharmacist involvement in HF management; leaves open confirmation by randomized trials before clinical adoption.
Heart failure (HF) is a clinical condition occurs when cardiac output is insufficient to meet the demands of tissue perfusion or does so by elevating filling pressure. HF is due to either systolic or diastolic dysfunction which reduces ventricular filling (diastolic dysfunction) and/or myocardial contractility (systolic dysfunction). Clinically, cardiac disease prevalence increases with individual age. Cardiac dysfunction occurs due to change in blood volume, and neurohumoral transmission status these desirable mechanisms to maintain adequate cardiac output and arterial blood pressure. The activation of three compensatory neurohormonal systems triggers the cardiac dysfunction leads to HF. Clinical pharmacist plays a role in disease management by identifying the risk factors, stage of severity, educating the patients and health-care practitioners and implementing the awareness programs, and modification of lifestyle interventions with in health-care system beneficial to the community may reduce the progression of disease severity.
No takes yet. Share an insight, caveat, or question.
Kondramutla Sravanthi (2021) conducted a review in Congestive Heart Failure. Clinical pharmacist management (risk factor identification, patient/provider education, awareness programs, lifestyle interventions) was evaluated on Progression of heart failure disease severity. Clinical pharmacist management through risk identification, education, awareness programs, and lifestyle interventions may reduce the progression of heart failure severity.
Synapse has enriched 10 related papers. Consider them for comparative context: